The point of care hematology diagnostics market size has grown strongly in recent years. It will grow from $2.9 billion in 2025 to $3.16 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to dependence on centralized laboratory testing, increasing burden of anemia and blood disorders, growth in hospital emergency admissions, need for faster diagnostic turnaround, limited access to laboratory infrastructure in rural areas.
The point of care hematology diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising prevalence of chronic and infectious diseases, expansion of point of care testing programs, increasing demand for rapid diagnostics in emergency care, technological advancements in compact hematology analyzers, growth in decentralized healthcare delivery models. Major trends in the forecast period include rising adoption of rapid bedside blood testing, growing demand for decentralized diagnostics in emergency settings, increasing use of portable and handheld hematology devices, expansion of point of care testing in resource-limited areas, focus on faster turnaround time for clinical decision-making.
The increasing prevalence of blood disorders is expected to drive the growth of the point-of-care hematology diagnostics market in the coming years. Blood disorders are conditions that affect components of the blood, including red blood cells, white blood cells, platelets, or plasma. Their rising incidence is largely due to the growing prevalence of chronic diseases, which directly impact blood health and necessitate ongoing monitoring. Point-of-care hematology diagnostics facilitate timely detection and monitoring by delivering rapid, accurate results at or near the site of patient care, enabling faster clinical decisions and improved disease management. For example, in March 2025, the American Cancer Society, a U.S.-based non-profit organization, reported that approximately 22,010 individuals are expected to be diagnosed with acute myeloid leukemia (AML), predominantly in adults, with around 11,090 projected deaths. AML accounts for roughly one-third of adult leukemia cases and about 1% of all cancers. Consequently, the rising incidence of blood disorders is propelling the growth of the point-of-care hematology diagnostics market.
Key companies in this market are developing advanced solutions, such as cartridge-based AI-powered hematology analyzers, to deliver rapid and precise on-site blood analysis. These compact devices utilize single-use reagent cartridges and artificial intelligence algorithms to perform complete blood counts (CBC) and other analyses directly at the point of care. For instance, in September 2024, Zoetis Inc., a US-based veterinary health company, launched Vetscan OptiCell, a cartridge-based, AI-powered hematology analyzer for veterinary use. This system provides rapid, reference-quality CBC results within minutes, while minimizing maintenance and hands-on time. It features AI-driven image analysis and viscoelastic focusing technology to accurately align cells, classify blood cells, and automatically detect abnormalities, ensuring reliable and efficient diagnostics.
In June 2023, Mars Inc., a US-based pet company, acquired Heska Corporation for an undisclosed amount. This acquisition expands Mars’ veterinary diagnostics capabilities and strengthens its position in advanced animal healthcare by leveraging Heska’s point-of-care hematology and specialty diagnostic solutions. Heska Corporation is a US-based veterinary diagnostics company offering point-of-care (POC) hematology diagnostics.
Major companies operating in the point of care hematology diagnostics market are F. Hoffmann‑La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Shenzhen Mindray Bio‑Medical Electronics Co. Ltd., Sysmex Corporation, HORIBA Ltd., Nova Biomedical Corp., S.D. Sight Diagnostics Ltd., EKF Diagnostics Holdings plc., BioMedomics Inc., PixCell Medical Technologies Ltd., Boule Diagnostics AB, Nihon Kohden Corporation, Edan Instruments Inc., A Menarini Industrie Farmaceutiche Srl, Becton Dickinson and Company, Ortho Clinical Diagnostics, Khema Diagnostics, Bio‑Rad Laboratories Inc.
North America was the largest region in the point of care hematology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point of care hematology diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point of care hematology diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the point of care hematology diagnostics market by increasing costs of imported diagnostic systems, reagents, and electronic components used in compact analyzers. Consumables and system segments are most affected, particularly in Asia-Pacific and Latin American regions that rely heavily on imported diagnostic devices. These cost pressures have influenced pricing and procurement decisions for hospitals and diagnostic centers. However, tariffs have also encouraged local manufacturing, regional sourcing of consumables, and innovation in cost-effective point of care diagnostic solutions.
The point of care hematology diagnostics market research report is one of a series of new reports that provides point of care hematology diagnostics market statistics, including point of care hematology diagnostics industry global market size, regional shares, competitors with a point of care hematology diagnostics market share, detailed point of care hematology diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the point of care hematology diagnostics industry. This point of care hematology diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Point-of-care hematology diagnostics refer to medical tests conducted at or near the site of patient care to quickly evaluate blood-related conditions, such as anemia, infections, or clotting disorders. These tests deliver rapid and accurate hematological results to support timely clinical decisions, particularly in emergency or resource-limited settings. This approach minimizes the reliance on centralized laboratory testing and accelerates diagnosis and treatment.
The primary types of point-of-care hematology diagnostics include complete blood count (CBC), coagulation testing, hemoglobin testing, anemia diagnosis, and others. A CBC measures various blood components, including red blood cells, white blood cells, hemoglobin, hematocrit, and platelets, helping to assess overall health and detect a wide range of disorders. These diagnostics are available as consumables and systems and are offered in both prescription-based and over-the-counter formats, serving end users such as diagnostic centers, hospitals, blood banks, transfusion centers, and other healthcare facilities.
The point of care hematology diagnostics market consists of revenues earned by entities by providing services such as rapid blood testing, decentralized diagnostic solutions, and home-based blood monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The point of care hematology diagnostics market also includes sales of portable hematology analyzers, cartridges and test kits, lancets, and reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The point of care hematology diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising prevalence of chronic and infectious diseases, expansion of point of care testing programs, increasing demand for rapid diagnostics in emergency care, technological advancements in compact hematology analyzers, growth in decentralized healthcare delivery models. Major trends in the forecast period include rising adoption of rapid bedside blood testing, growing demand for decentralized diagnostics in emergency settings, increasing use of portable and handheld hematology devices, expansion of point of care testing in resource-limited areas, focus on faster turnaround time for clinical decision-making.
The increasing prevalence of blood disorders is expected to drive the growth of the point-of-care hematology diagnostics market in the coming years. Blood disorders are conditions that affect components of the blood, including red blood cells, white blood cells, platelets, or plasma. Their rising incidence is largely due to the growing prevalence of chronic diseases, which directly impact blood health and necessitate ongoing monitoring. Point-of-care hematology diagnostics facilitate timely detection and monitoring by delivering rapid, accurate results at or near the site of patient care, enabling faster clinical decisions and improved disease management. For example, in March 2025, the American Cancer Society, a U.S.-based non-profit organization, reported that approximately 22,010 individuals are expected to be diagnosed with acute myeloid leukemia (AML), predominantly in adults, with around 11,090 projected deaths. AML accounts for roughly one-third of adult leukemia cases and about 1% of all cancers. Consequently, the rising incidence of blood disorders is propelling the growth of the point-of-care hematology diagnostics market.
Key companies in this market are developing advanced solutions, such as cartridge-based AI-powered hematology analyzers, to deliver rapid and precise on-site blood analysis. These compact devices utilize single-use reagent cartridges and artificial intelligence algorithms to perform complete blood counts (CBC) and other analyses directly at the point of care. For instance, in September 2024, Zoetis Inc., a US-based veterinary health company, launched Vetscan OptiCell, a cartridge-based, AI-powered hematology analyzer for veterinary use. This system provides rapid, reference-quality CBC results within minutes, while minimizing maintenance and hands-on time. It features AI-driven image analysis and viscoelastic focusing technology to accurately align cells, classify blood cells, and automatically detect abnormalities, ensuring reliable and efficient diagnostics.
In June 2023, Mars Inc., a US-based pet company, acquired Heska Corporation for an undisclosed amount. This acquisition expands Mars’ veterinary diagnostics capabilities and strengthens its position in advanced animal healthcare by leveraging Heska’s point-of-care hematology and specialty diagnostic solutions. Heska Corporation is a US-based veterinary diagnostics company offering point-of-care (POC) hematology diagnostics.
Major companies operating in the point of care hematology diagnostics market are F. Hoffmann‑La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Shenzhen Mindray Bio‑Medical Electronics Co. Ltd., Sysmex Corporation, HORIBA Ltd., Nova Biomedical Corp., S.D. Sight Diagnostics Ltd., EKF Diagnostics Holdings plc., BioMedomics Inc., PixCell Medical Technologies Ltd., Boule Diagnostics AB, Nihon Kohden Corporation, Edan Instruments Inc., A Menarini Industrie Farmaceutiche Srl, Becton Dickinson and Company, Ortho Clinical Diagnostics, Khema Diagnostics, Bio‑Rad Laboratories Inc.
North America was the largest region in the point of care hematology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point of care hematology diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point of care hematology diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the point of care hematology diagnostics market by increasing costs of imported diagnostic systems, reagents, and electronic components used in compact analyzers. Consumables and system segments are most affected, particularly in Asia-Pacific and Latin American regions that rely heavily on imported diagnostic devices. These cost pressures have influenced pricing and procurement decisions for hospitals and diagnostic centers. However, tariffs have also encouraged local manufacturing, regional sourcing of consumables, and innovation in cost-effective point of care diagnostic solutions.
The point of care hematology diagnostics market research report is one of a series of new reports that provides point of care hematology diagnostics market statistics, including point of care hematology diagnostics industry global market size, regional shares, competitors with a point of care hematology diagnostics market share, detailed point of care hematology diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the point of care hematology diagnostics industry. This point of care hematology diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Point-of-care hematology diagnostics refer to medical tests conducted at or near the site of patient care to quickly evaluate blood-related conditions, such as anemia, infections, or clotting disorders. These tests deliver rapid and accurate hematological results to support timely clinical decisions, particularly in emergency or resource-limited settings. This approach minimizes the reliance on centralized laboratory testing and accelerates diagnosis and treatment.
The primary types of point-of-care hematology diagnostics include complete blood count (CBC), coagulation testing, hemoglobin testing, anemia diagnosis, and others. A CBC measures various blood components, including red blood cells, white blood cells, hemoglobin, hematocrit, and platelets, helping to assess overall health and detect a wide range of disorders. These diagnostics are available as consumables and systems and are offered in both prescription-based and over-the-counter formats, serving end users such as diagnostic centers, hospitals, blood banks, transfusion centers, and other healthcare facilities.
The point of care hematology diagnostics market consists of revenues earned by entities by providing services such as rapid blood testing, decentralized diagnostic solutions, and home-based blood monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The point of care hematology diagnostics market also includes sales of portable hematology analyzers, cartridges and test kits, lancets, and reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Point of Care Hematology Diagnostics Market Characteristics
3. Point of Care Hematology Diagnostics Market Supply Chain Analysis
4. Global Point of Care Hematology Diagnostics Market Trends and Strategies
5. Point of Care Hematology Diagnostics Market Analysis of End Use Industries
7. Global Point of Care Hematology Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Point of Care Hematology Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. Point of Care Hematology Diagnostics Market Segmentation
10. Point of Care Hematology Diagnostics Market Regional and Country Analysis
11. Asia-Pacific Point of Care Hematology Diagnostics Market
12. China Point of Care Hematology Diagnostics Market
13. India Point of Care Hematology Diagnostics Market
14. Japan Point of Care Hematology Diagnostics Market
15. Australia Point of Care Hematology Diagnostics Market
16. Indonesia Point of Care Hematology Diagnostics Market
17. South Korea Point of Care Hematology Diagnostics Market
18. Taiwan Point of Care Hematology Diagnostics Market
19. South East Asia Point of Care Hematology Diagnostics Market
20. Western Europe Point of Care Hematology Diagnostics Market
21. UK Point of Care Hematology Diagnostics Market
22. Germany Point of Care Hematology Diagnostics Market
23. France Point of Care Hematology Diagnostics Market
24. Italy Point of Care Hematology Diagnostics Market
25. Spain Point of Care Hematology Diagnostics Market
26. Eastern Europe Point of Care Hematology Diagnostics Market
27. Russia Point of Care Hematology Diagnostics Market
28. North America Point of Care Hematology Diagnostics Market
29. USA Point of Care Hematology Diagnostics Market
30. Canada Point of Care Hematology Diagnostics Market
31. South America Point of Care Hematology Diagnostics Market
32. Brazil Point of Care Hematology Diagnostics Market
33. Middle East Point of Care Hematology Diagnostics Market
34. Africa Point of Care Hematology Diagnostics Market
36. Point of Care Hematology Diagnostics Market Competitive Landscape and Company Profiles
37. Point of Care Hematology Diagnostics Market Other Major and Innovative Companies
40. Point of Care Hematology Diagnostics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Point Of Care Hematology Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses point of care hematology diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for point of care hematology diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The point of care hematology diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Complete Blood Count; Coagulation Testing; Hemoglobin Testing; Anemia Diagnosis; Other Types2) By Mode Of Prescription: Prescription Based Product; Over-The-Counter Based Product
3) By End User: Diagnostic Centers; Hospitals; Blood Banks; Transfusion Centers; Other End Users
Subsegments:
1) By Complete Blood Count: White Blood Cell Count; Red Blood Cell Count; Platelet Count; Hematocrit; Hemoglobin Concentration; Mean Corpuscular Volume (MCV)2) By Coagulation Testing: Prothrombin Time (PT); Activated Partial Thromboplastin Time (aPTT); International Normalized Ratio (INR); D-Dimer Test; Fibrinogen Level
3) By Hemoglobin Testing: Total Hemoglobin; Glycated Hemoglobin (HbA1c); Oxyhemoglobin; Carboxyhemoglobin; Methemoglobin
4) By Anemia Diagnosis: Iron Studies; Vitamin B12 Levels; Folate Levels; Reticulocyte Count; Ferritin Test; Transferrin Saturation
5) By Other Types: Blood Typing And Crossmatching; Erythrocyte Sedimentation Rate; Malaria Parasite Detection; Sickle Cell Screening; C-Reactive Protein Testing
Companies Mentioned: F. Hoffmann‑La Roche Ltd.; Abbott Laboratories; Danaher Corporation; Siemens Healthineers AG; Shenzhen Mindray Bio‑Medical Electronics Co. Ltd.; Sysmex Corporation; HORIBA Ltd.; Nova Biomedical Corp.; S.D. Sight Diagnostics Ltd.; EKF Diagnostics Holdings plc.; BioMedomics Inc.; PixCell Medical Technologies Ltd.; Boule Diagnostics AB; Nihon Kohden Corporation; Edan Instruments Inc.; A Menarini Industrie Farmaceutiche Srl; Becton Dickinson and Company; Ortho Clinical Diagnostics; Khema Diagnostics; Bio‑Rad Laboratories Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Point of Care Hematology Diagnostics market report include:- F. Hoffmann‑La Roche Ltd.
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthineers AG
- Shenzhen Mindray Bio‑Medical Electronics Co. Ltd.
- Sysmex Corporation
- HORIBA Ltd.
- Nova Biomedical Corp.
- S.D. Sight Diagnostics Ltd.
- EKF Diagnostics Holdings plc.
- BioMedomics Inc.
- PixCell Medical Technologies Ltd.
- Boule Diagnostics AB
- Nihon Kohden Corporation
- Edan Instruments Inc.
- A Menarini Industrie Farmaceutiche Srl
- Becton Dickinson and Company
- Ortho Clinical Diagnostics
- Khema Diagnostics
- Bio‑Rad Laboratories Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.16 Billion |
| Forecasted Market Value ( USD | $ 4.39 Billion |
| Compound Annual Growth Rate | 8.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
